Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perindopril erbumine
Drug ID BADD_D01740
Description Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Indications and Usage For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Marketing Status Prescription; Discontinued
ATC Code C09AA04
DrugBank ID DB00790
KEGG ID D00624
MeSH ID D020913
PubChem ID 441313
TTD Drug ID D03KYG
NDC Product Code 0054-0110; 65862-288; 66039-804; 65862-286; 0054-0112; 50370-0005; 65862-287; 15308-1000; 53104-7586; 0054-0111
Synonyms Perindopril | Pirindopril | S-9490 | S 9490 | S9490 | S 9490-3 | S 9490 3 | S 94903 | Perindopril Erbumine | Erbumine, Perindopril | Perstarium
Chemical Information
Molecular Formula C23H43N3O5
CAS Registry Number 107133-36-8
SMILES CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O.CC(C)(C)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood pressure decreasedAngiotensin-converting enzymeP12821T82577Not Available
CoughB2 bradykinin receptorP30411T23714Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.007--
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal pain07.01.05.005--
Gout15.01.06.001; 14.09.01.001--Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hyperkinesia17.01.02.008--Not Available
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Illusion19.10.02.005--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Intermittent claudication24.04.03.001--Not Available
Intestinal infarction24.04.08.008; 07.15.02.006--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Lacrimation increased06.08.02.004--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Local swelling08.01.03.013--Not Available
Loss of consciousness17.02.04.004--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages